BOSTON, September 19, 2016— Rhythm announced today that it has been named to the annual FierceBiotech “Fierce 15,” designating Rhythm as one of the top privately held biotechnology companies of 2016 with the potential to have a major impact on the treatment of human diseases. Rhythm is developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.
“Rhythm is honored to be recognized as one of the innovative companies selected for this year’s ‘Fierce 15’,” said Keith Gottesdiener, CEO of Rhythm. “We credit our talented team and our clinical collaborators who are working with us to change the treatment of severe obesity caused by genetic defects.”
The “Fierce 15” celebrates the spirit of being “fierce”—championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fourteenth annual “Fierce 15” selection. The 2016 list of “Fierce 15” companies can be found online at http://www.fiercebiotech.com/special-report/fiercebiotech-s-2016-fierce-15.
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news, and more. More than 160,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
About Rhythm (www.rhythmtx.com)
Rhythm is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first-in-class melanocortin 4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. Rhythm supports The Genetic Obesity Project (www.GeneticObesity.com), which is dedicated to improving the understanding of severe obesity that is caused by specific genetic defects. The company is based in Boston, Massachusetts.